Pfizer: I'm Still Expecting A Massive Rebound

AI Briefing

• – Pfizer reports strong Q4 earnings, driven by Seagen acquisition and growth in its oncology business
• – Pharmaceutical giant sees 'obesity upside' in 2023, citing favorable trends in its cholesterol and diabetes treatments
• – Pfizer's acquisition of Seagen boosts its pipeline and expands its presence in the cancer therapy market